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Background: The aims of the present analysis are to estimate the prevalence of five key 
chronic cardiovascular, metabolic and renal conditions at the population level, the prevalence 
of renin–angiotensin–aldosterone system inhibitor (RAASI) medication use and the magni-
tude of potassium (K+) derangements among RAASI users.
Methods and Results: We used data from more than 375,000 individuals, 55 years of age or 
older, included in the population-based healthcare database of the Catalan Institute of Health 
between 2015 and 2017. The conditions of interest were chronic heart failure (CHF), chronic 
kidney disease (CKD), diabetes mellitus, ischemic heart disease and hypertension. RAASI 
medications included angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, 
mineralocorticoid receptor antagonists (MRAs) and renin inhibitors. Hyperkalemia was defined 
as K+ levels >5.0 mEq/L and hypokalemia as K+ <3.5 mEq/L. The prevalence of chronic 
cardiovascular, metabolic and renal conditions was high, and particularly that of hypertension 
(prevalence ranging from 48.2% to 48.9%). The use of at least one RAASI medication was almost 
ubiquitous in these patients (75.2–77.3%). Among RAASI users, the frequency of K+ derange-
ments, mainly of hyperkalemia, was very noticeable (12% overall), particularly in patients with 
CKD or CHF, elderly individuals and users of MRAs. Hypokalemia was less frequent (1%).
Conclusion: The high prevalence of K+ derangements, and particularly hyperkalemia, 
among RAASI users highlights the real-world relevance of K+ derangements, and the 
importance of close monitoring and management of K+ levels in routine clinical practice. 
This is likely to benefit a large number of patients, particularly those at higher risk.
Keywords: chronic heart failure, chronic kidney disease, heart failure, hyperkalemia, 
hypertension, potassium
Introduction
Potassium (K+) is the most common cation in the human body. K+ is the main 
intracellular electrolyte, having several important physiological functions including 
maintenance of the electrical action potential across cell membranes, particularly in 
the myocardium; cell metabolism, glycogen and protein synthesis.1 Hypokalemia and 
hyperkalemia are both common K+ homeostasis disorders, with the potential to cause 
life-threatening arrhythmias2 via electrophysiological perturbations of the cell mem-
brane. Hypokalemia – defined as serum K+ <3.5 mEq/L – is typically the result of 
extracellular changes in K+ levels due to excessive excretion, i.e., diarrhea or diuretic 
treatment, while hyperkalemia – serum K+ >5 mEq/L – results from extracellular 
shifts of K+, excessive ingestion of this electrolyte and/or impaired kidney function.3
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In patients with chronic cardiovascular disorders, K+ 
homeostasis is often frail, particularly in the presence of 
renin–angiotensin–aldosterone system inhibition (RAASI) 
therapies,3 such as angiotensin-converting enzyme inhibi-
tors (ACEIs), angiotensin II receptor blockers (ARBs), 
renin inhibitors (RIs; e.g., aliskiren), angiotensin II recep-
tor blocker neprilysin inhibitors (ARNIs) and mineralocor-
ticoid-receptor antagonists (MRAs). On the other hand, 
loop or thiazide diuretics, which are also frequently used 
in these patients, can reduce hyperkalemia and even cause 
hypokalemia.2,4-6 In this context, current clinical practical 
guidelines for the management of these patients recom-
mend close monitoring of their renal function and K+ 
levels, particularly in the presence of pharmacological 
therapy changes or drug titration,6–8 although these recom-
mendations are not always implemented.9
Hyperkalemia and hypokalemia have been associated 
with higher all-cause mortality in observational studies.2,10 
In addition, K+ derangements may limit the use and titra-
tion of key, class I medications in these patients, including 
RAASI therapies.11 Nevertheless, very limited epidemio-
logical data on their importance at a population level are 
available.12 Characterizing the real-world epidemiology of 
K+ derangements may be particularly important in patients 
with conditions such as chronic heart failure (CHF), 
chronic kidney disease (CKD), diabetes mellitus (DM), 
ischemic heart disease (IHD) and hypertension (HTN), in 
all of which RAASI therapies are often used.6–8
The purpose of this study was thus to gain a better 
understanding, from a population-level, real-world per-
spective, of 1) the prevalence of these five conditions in 
the general population; 2) the frequency of RAASI use 
among those patients; and 3) the magnitude of K+ derange-
ments among individuals with these conditions, particu-
larly among patients using RAASI medications.
Materials and Methods
Data Source
We used the population-based healthcare database of the 
Catalan Institute of Health (Institut Catala de Salut, ICS). 
This is a longitudinal database that includes detailed 
healthcare information from primary care, as well as 
from eight large hospitals, for all residents of Catalonia 
(Spain). Specifically, the database comprises exhaustive, 
quality-controlled, detailed, individual-level data on 
sociodemographic characteristics, medical conditions and 
medication dispensing, among other variables. Medical 
conditions are coded using either the International 
Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) coding system for in-hospital 
diagnoses or the International Classification of Diseases, 
10th Revision (ICD-10) coding system for primary care 
diagnoses, and the Clinical Classifications Software 
(CCS) for both. Medication dispensing is coded using 
the Anatomical Therapeutic Chemical (ATC) coding 
system.
For the present analysis, this clinical database was 
linked to a laboratory test database, which includes any 
routine care laboratory test results from both hospital care 
and primary care settings generated since January 1st 
2015.
Study Population
Analyses were restricted to the Metropolitana Sud 
(MetroSud) healthcare area of Barcelona (Catalonia, 
Spain) (Figure 1), which comprises approximately 
1.2 million individuals and has Bellvitge University 
Hospital as the tertiary reference hospital. The healthcare- 
related information of these individuals is captured auto-
matically and exhaustively by the database. Inclusion cri-
teria for the present analysis were age 55 years or older 
and being alive at study entry. No exclusion criteria were 
applied.
Study Period
For the purposes of the present analysis, the study period 
was set between January 1st 2015 and December 31st 
2017. The start of the study period was defined by the 
date on which laboratory test results became available in 
the database. For primary care diagnoses, any historical 
information available in the database was used; for hospi-
tal diagnoses, we used the information for the years 2014– 
2017.
Definitions and Data Collection
The chronic cardiovascular, metabolic and renal conditions 
of interest were CHF, CKD, DM, IHD and HTN. Evidence 
of each of these diagnoses was searched for in the database 
using operational definitions combining ICD-9-CM, ICD- 
10 and CCS codes (see Supplementary Tables S1–S3).
The drugs of interest were RAASI medications, which 
include ACEIs, ARBs, MRAs and RIs. Use of these med-
ications was identified in the pharmacy dispensing compo-
nent of the database, using operational definitions 
combining ATC codes (Table S4). Specifically, the recent 
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drug combination sacubitril/valsartan was assessed as part 
of the ARB group.
For the analyses, hyperkalemia was defined as evi-
dence of serum K+ levels >5.0 mEq/L and hypokalemia 
as serum K+ levels <3.5 mEq/L.
Statistical Analyses
To assess the frequency of CHF, CKD, DM, IHD and HTN 
in the general population, three retrospective assessments, 
on January 1st 2015, January 1st 2016 and January 1st 
2017, were performed. At each time point, the proportion 
of individuals with each of these diagnoses, as well as the 
proportion of individuals with at least one of the diag-
noses, was calculated using all the historical information 
available in the database at that time point, among indivi-
duals included in the study population for each study 
period.
A retrospective approach was also used to assess the 
frequency of RAASI medication use among patients with 
the conditions of interest. Specifically, at each time point 
(January 1st 2015, January 1st 2016 and January 1st 
2017), the proportion of individuals using, during the 
preceding year, any (i.e., at least one) RAASI medication, 
and each RAASI medication subgroup, was calculated 
among individuals with recorded evidence of at least one 
of the relevant chronic conditions of interest.
To evaluate the frequency of K+ derangements among 
individuals with chronic cardiovascular, metabolic and renal 
conditions, at each time point, the occurrence of at least one 
episode of hyperkalemia, hypokalemia or any K+ derange-
ment, as well as the occurrence of two or more episodes of 
hyperkalemia (“recurrent hyperkalemia”), were assessed by 
evaluating any laboratory test results of serum K+ levels 
available during the preceding year, among individuals 
with recorded evidence of CHF, CKD, DM, IHD and 
HTN. Individuals with no available data on serum K+ levels 
during the respective period of evaluation were managed in 
two ways: assuming normokalemia (i.e., included in the 
denominator of the prevalence calculations) and as missing 
data (i.e., excluded from the denominator).
To evaluate the frequency of K+ derangements specifi-
cally among individuals with any of the relevant condi-
tions and using RAASI medications, the preceding 
analysis was repeated but restricted to individuals with 
CHF, CKD, DM, IHD and HTN and using at least one 
RAASI medication during the preceding year.
To identify determinants of prevalent hyperkalemia, 
a multivariable analysis was performed, with log- 
binomial regression for each year (2015, 2016 and 2017). 
The factors analyzed were age, sex, prevalence of CHF, 
CKD, DM, IHD and HTN, and treatment with ACEIs, 
ARBs and MRAs in the previous year. After that, the 
risk ratios for prevalence of hyperkalemia among these 
variables were calculated. The models of the multivariable 
analysis were presented as the risk ratio with correspond-
ing 95% confidence interval.
Figure 1 Metropolitana Sud Area (MetroSud), Barcelona, Spain. 
Abbreviation: m, millions.
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In post hoc analyses, all calculations were repeated 
specifically for the subgroup of patients with CHF and 
either CKD or DM.
Ethics in Research
The present study was approved by the Ethics in Research 
Committee of the Bellvitge University Hospital and 
Bellvitge Biomedical Research Institute (IDIBELL).
Results
Study Population
Between January 1st 2015 and January 1st 2017, there was 
a slight growth in the population of the MetroSud Area 
(Figure 2). Consistent with this, the study population 
included in the analyses also experienced a slight increase, 
comprising 362,281 individuals on January 1st 2015 and 
375,233 on January 1st 2017, all of whom were 55 years 
of age or older at study entry.
Prevalence of CHF, CKD, DM, IHD and 
HTN
HTN was very frequent, and affected almost half of the 
study population, with a prevalence ranging from 48.2% 
to 48.9% (Table 1). The prevalence of DM was 
the second highest, ranging from 14.6% to 14.8%. On 
the other hand, CHF was the least frequent of the five 
conditions, affecting 2.2–3.2% of the study population. 
The proportion of individuals with any (i.e., at least 
one) of the relevant conditions was approximately 
54%. The prevalence of CHF, CKD and IHD increased 
over time.
Among individuals with CHF, the frequency of CKD and 
of DM was very high (Table S5), ranging from 49.8% 
to 54.2%.
Frequency of RAASI Medication Use 
Among Individuals with CHF, CKD, DM, 
IHD or HTN
During the study period, the use of ACEIs among indivi-
duals with any of the relevant conditions was very high, 
with a 5% increase in this proportion between 2015 
(52.9%) and 2017 (57.5%) (Table 2). The use of ARBs 
was also high, with a slight increase over time (31.2% in 
2015, 32.4% in 2017). On the other hand, the use of RIs 
was consistently marginal in the three study periods. The 
frequency of use of at least one RAASI medication ranged 
between 75.2% in 2015 and 77.3% in 2017.
Prevalence of K+ Derangements Among 
Individuals with CHF, CKD, DM, IHD or 
HTN
Hyperkalemia was a very frequent event, ranging from 
10.6% when all individuals with at least one relevant condi-
tion were included in the calculations (i.e., regardless of 
whether they had had their K+ levels assessed during the 
period of evaluation) (Table 3, left columns) to 12.8% when 
only patients with at least one K+ measurement during the 
period of evaluation were considered (Table 3, right col-
umns). On the other hand, hypokalemia was a less frequent 
event, ranging from 1.0% to 1.2%. The frequency of at least 
one episode of any K+ derangement (i.e., either hyperkalemia 
or hypokalemia) was up to 14% among individuals with K+ 
Figure 2 Study population, 2015–2017. These three flowcharts present the flow of the study population included in the analyses in each of the three study periods (2015, 
2016 and 2017). 
Abbreviations: MetroSud, Metropolitana Sud; N, number.
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data available. The prevalence of recurrent hyperkalemia 
ranged from 1.8% 2.6%. There was a trend towards an 
increase over time in the occurrence of K+ derangements.
Figure 3 displays the prevalence of K+ derangements 
among individuals with each of the relevant conditions. 
Although hyperkalemia was highly prevalent across all of 
them, the highest frequencies were 26% for CKD, fol-
lowed by CHF (panel A). The highest frequency of hypo-
kalemia was also observed in patients with CHF.
The frequency of K+ derangements among indivi-
duals with CHF and CKD simultaneously is presented 
in Table S6. In this subgroup of patients, hyperkalemia 
was even more frequent than in the overall studied 
population (23.3–24.6%). The prevalence of recurrent 
hyperkalemia was also very high in this subgroup 
(6.7–8.0%).
Prevalence of K+ Derangements Among 
Individuals with CHF, CKD, DM, IHD or 
HTN and Using RAASI Medications
The frequency of hyperkalemia among patients with at 
least one of the relevant chronic conditions and using 
RAASI medications was slightly more frequent (12%) 
(Table 4) than when the RAASI use criterion was not 
considered. On the other hand, the frequency of hypoka-
lemia remained low. In analyses stratified by age, all K+ 
derangements were more frequent with older age 
(Table S7).
Table 1 Prevalence of CHF, CKD, DM, IHD and HTN Among Adults ≥55 Years of Age, MetroSud Area, Catalonia, January 1st 2015 to 
January 1st 2017
Total N CHF CKD DM IHD HTN Any
2015 362,281
No. of cases 8140 20,544 53,423 8873 174,712 194,719
Prevalence 2.2 5.7 14.7 2.4 48.2 53.7
2016 368,362
No. of cases 10,507 26,478 54,471 12,423 180,066 199,820
Prevalence 2.9 7.2 14.8 3.4 48.9 54.2
2017 375,233
No. of cases 12,062 30,592 54,925 15,101 182,490 202,255
Prevalence 3.2 8.2 14.6 4.0 48.6 53.9
Notes: Data are presented as number of cases, or prevalence (in %). For each year, prevalent diagnoses were assessed using all historical information available in the 
database as of January 1st (e.g., for 2015, prevalent diagnoses were identified using all cumulative information available as of January 1st 2015), among individuals included in 
the study population for each study period. 
Abbreviations: CHF, chronic heart failure; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; IHD, ischemic heart disease; N, number; No., number.
Table 2 Prevalence of Use of ACEI, ARB, MRA and RI Among Adults ≥55 Years of Age with at Least One of the Relevant 
Conditions (CHF, CKD, DM, IHD, HTN), MetroSud Area, Catalonia, January 1st 2015 to January 1st 2017
Total N ACEIs ARBs MRAs RIs Any
2015 194,719
No. of cases 102,992 60,744 5606 1056 146,402
Prevalence 52.9 31.2 2.9 0.5 75.2
2016 199,820
No. of cases 110,371 63,396 6116 1033 152,180
Prevalence 55.2 31.7 3.1 0.5 76.2
2017 202,255
No. of cases 116,255 65,525 6518 992 156,411
Prevalence 57.5 32.4 3.2 0.5 77.3
Notes: Data are presented as number of individuals, or prevalence (in %). For each year, prevalent use of medications was assessed between January 1st of the 
preceding year and January 1st of the corresponding year (e.g., for 2015, prevalent use was identified between January 1st 2014 and January 1st 2015), among 
individuals from the study population with recorded evidence of at least one of the conditions of interest. 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHF, chronic heart failure; CKD, chronic kidney disease; DM, 
diabetes mellitus; HTN, hypertension; IHD, ischemic heart disease; MRA, mineralocorticoid receptor antagonist; N, number; No., number; RI, renin inhibitor.
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Figure 4 displays the frequency of K+ derangements by 
RAASI medication subgroup. All K+ disorders were more 
frequent in patients treated with MRAs, hyperkalemia 
being present in 20–22% of MRA users.
Risk Factors for Hyperkalemia
Table 5 shows the models of the multivariable analysis. 
The models display risk ratios (RRs) with corresponding 
95% confidence intervals (CIs). All the variables ana-
lyzed were related to a higher prevalence of hyperkale-
mia. The strongest estimators for hyperkalemia were 
CKD (RR 1.8–1.9; p<0.001) and DM (RR 1.85–1.9; 
p<0.001), among the chronic conditions. Between the 
RAASI medications, the highest magnitude relation 
was with ACEIs (RR 1.39–1.5; p<0.001) and MRA 
(RR 1.34–1.4; p<0.001). Male gender and age were 
slightly related to the prevalence of hyperkalemia 
between 2015 and 2017.
Prevalence of Hyperkalemia, Defined as 
K+>5.5 mEq/L
Among patients with at least one relevant condition and 
taking at least one RAASI drug, the prevalence of K+ >5.5 
mEq/L was 2.0–2.1% (Table S8).
Discussion
In this very large, population-based analysis including 
the whole population from the MetroSud Area 
(Catalonia) 55 years of age or older, the prevalence of 
CHF, CKD, DM, IHD and HTN was high. Among these 
patients, the use of at least one RAASI medication was 
almost ubiquitous; and among those users, the frequency 
of K+ derangements and particularly of hyperkalemia 
was very noticeable, especially in patients with CKD, 
patients with CHF, elderly individuals and users of 
MRAs. We identified factors related to the prevalence 
of hyperkalemia, notably elderly age and male sex, and 
with higher risk for the presence of CKD or DM, and the 
use of ACEIs and MRAs. These findings highlight the 
real-world importance of K+ derangements among these 
patients, and stress the importance of close monitoring 
and management of K+ levels in routine clinical practice 
(particularly in subgroups at higher risk of dyskalemia), 
which are likely to benefit a large number of patients.
To our knowledge, this is the first study to evaluate the 
real-world importance of K+ abnormalities (detected in 
both hospital and primary care settings) across several 
chronic cardiovascular and metabolic conditions, diag-
nosed in both ambits. Prior research using alternative 
study designs and data sources, and including disparate 
Table 3 Prevalence of Potassium Derangements Among Adults ≥55 Years of Age with at Least One Relevant Condition (CHF, CKD, 
DM, IHD, HTN), MetroSud Area, Catalonia, January 1st 2015 to January 1st 2017
All At Least One K+ Assessment Available
Total 
N













No. of cases – – – – – – – –
Prevalence – – – – – – – –
2016 199,820 174,424
No. of cases 21,164 2040 23,157 3644 21,164 2040 23,157 3644
Prevalence 10.6 1.0 11.6 1.8 12.1 1.2 13.3 2.1
2017 202,255 176,942
No. of cases 22,615 2208 24,770 4666 22,615 2208 24,770 4666
Prevalence 11.2 1.1 12.2 2.3 12.8 1.2 14.0 2.6
Notes: Data are presented as number of cases, or prevalence (in %). For each year, prevalence was assessed between January 1st of the preceding year and January 1st of 
the corresponding year (e.g., for 2016, prevalence of hyperkalemia was assessed between January 1st 2015 and January 1st 2016), among individuals from the study 
population with recorded evidence of at least one of the conditions of interest. Serum K+ levels were not available before January 1st 2015. On the left, calculations include 
all individuals with at least one chronic CV condition, regardless of whether they had their K+ assessed during the relevant study period. On the right, calculations include 
individuals with at least one chronic CV condition and with at least one K+ measurement available during the corresponding period of evaluation. 
Abbreviations: CHF, chronic heart failure; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; hyperK, hyperkalemia; hypoK, hypokalemia; IHD, 
ischemic heart disease; K+, potassium; N, number; No., number.
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Figure 3 Prevalence of hyperkalemia, hypokalemia and any potassium derangement (hyperkalemia or hypokalemia) among individuals ≥55 years of age with each of the 
relevant chronic conditions, MetroSud Area, Catalonia, January 1st 2016 and January 1st 2017. (A) Hyperkalemia. (B) Hypokalemia. (C) Any (hyperkalemia or hypokalemia). 
For each year, prevalence was assessed between January 1st of the preceding year and January 1st of the corresponding year. Calculations included all individuals with 
recorded evidence of each of the relevant diseases, regardless of whether they had their K+ levels assessed during the relevant study period. 
Abbreviations: CHF, chronic heart failure; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; IHD, ischemic heart disease.
Dovepress                                                                                                                                              Jiménez-Marrero et al
Clinical Epidemiology 2020:12                                                                                               submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       






























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
study populations in terms of age and comorbidities, have 
yielded very heterogeneous findings. For example, the 
frequency of hyperkalemia in some clinical trials has 
been reported to be as low as 2–3%, although it increases 
up to 32% in some patients treated with RAASI 
medications.12–15
Similarly, large variability has been reported in obser-
vational studies, where the prevalence of hyperkalemia has 
been reported to be around 3% in the general population,16 
reaching up to 25% in patients with CHF, DM or CKD,17 
and up to 50% in some cohorts of patients with severe 
CKD.18 The variability across studies in terms of the 
threshold used to define hyperkalemia (typically ranging 
from 5.0 to 6.0 mEq/L)12–18 may have also contributed to 
the heterogeneous estimations. Consistent with this, in our 
study the prevalence of hyperkalemia decreased when an 
alternative, more restrictive cut-off point (>5.5 mEq/L) 
was used.
Focusing specifically on heart failure, in a Danish 
cohort almost 40% of CHF patients developed at least 
one episode of hyperkalemia during a mean of 2.2 years 
of follow-up. Recurrent hyperkalemia was also a very 
frequent finding.19 There was also a recent study in our 
environment from Spanish hospitals included in the regis-
try of the European Society of Cardiology, with 
a prevalence of hyperkalemia (defined as K+ >5.4 mEq/ 
L) of 4.3% and 8.3% in patients with chronic and acute 
heart failure, respectively; other conditions and 
hypokalemia were not evaluated.20 In our study, hyperka-
lemia was highly frequent among patients with CHF, the 
prevalence becoming even higher in the presence of con-
current predisposing conditions such as CKD or RAASI 
medication. In the multivariable analysis, CHF was asso-
ciated with the prevalence of hyperkalemia, although not 
achieving statistical significance in the years 2016 and 
2017. When a higher threshold was implemented, the 
prevalence of hyperkalemia was still significant, but 
lower compared with CHF patients in the Spanish 
study;20 this may be due to the hospital-based character-
istic of this registry, in contrast to our wider, population- 
based data, coming from both hospital and primary care 
databases.
We also observed a trend towards a higher prevalence 
of hyperkalemia with older age. This was expected, as 
elderly patients are frail and are often treated with several 
co-medications, both of which increase the likelihood of 
K+ abnormalities. Also, hyperkalemia was more frequent 
in patients under MRA therapy. This may be the conse-
quence of the fact that MRA is a second-step pharma-
cotherapy in the management of conditions such as CHF 
or HTN.7,21,22 This means that an important proportion of 
these individuals were also being treated with ARBs or 
ACEIs simultaneously with MRA, increasing the risk of 
developing hyperkalemia.
Our study has important implications. Hyperkalemia 
and hypokalemia have both been associated with increased 
Table 4 Prevalence of Potassium Derangements Among Adults ≥55 Years of Age with at Least One Relevant Condition (CHF, CKD, 
DM, IHD, HTN) and Taking at Least One Relevant Drug (ACEIs, ARBs, MRAs, RIs), MetroSud Area, Catalonia, January 1st 2015 to 
January 1st 2017
Total N HyperK HypoK HyperK or HypoK Recurrent HyperK
2015 146,402
No. of cases – – – –
Prevalence – – – –
2016 152,180
No. of cases 17,517 1605 19,083 3081
Prevalence 11.5 1.1 12.5 2.0
2017 156,411
No. of cases 18,810 1755 20,522 3972
Prevalence 12.0 1.1 13.1 2.5
Notes: Data are presented as number of cases, or prevalence (in %). For each year, prevalence was assessed between January 1st of the preceding year and January 1st of 
the corresponding year (e.g., for 2016, prevalence of hyperkalemia was assessed between January 1st 2015 and January 1st 2016), among individuals from the study 
population with recorded evidence of at least one of the conditions of interest and using at least one RAASI medication (regardless of whether they had their K+ assessed 
during the relevant study period). Serum K+ levels were not available before January 1st 2015. 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHF, chronic heart failure; CKD, chronic kidney disease; DM, diabetes 
mellitus; HTN, hypertension; hyperK, hyperkalemia; hypoK, hypokalemia; IHD, ischemic heart disease; K+, potassium; MRA, mineralocorticoid receptor antagonist; N, 
number; No., number; RIs, renin inhibitor.
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Figure 4 Prevalence of hyperkalemia, hypokalemia and any potassium derangement (hyperkalemia or hypokalemia) in adults ≥55 years of age with at least one of the 
relevant chronic conditions, by RAASI drug subgroups, MetroSud Area, Catalonia, January 1st 2016 and January 1st 2017. (A) Hyperkalemia. (B) Hypokalemia. (C) Any 
(hyperkalemia or hypokalemia). Data are presented as prevalence (in %). For each year, prevalence was assessed between January 1st of the preceding year and January 1st of 
the corresponding year (e.g., for 2016, prevalence of hyperkalemia was assessed between January 1st 2015 and January 1st 2016), among individuals from the study 
population with recorded evidence of at least one of the conditions of interest (regardless of whether they had their K+ assessed during the relevant study period). Serum 
K+ levels were not recorded before January 1st 2015. Patients using each drug could also be using the other study drugs (i.e., groups were not mutually exclusive). 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blocker; CHF, chronic heart failure; CKD, chronic kidney disease; DM, diabetes 
mellitus; HTN, hypertension; hyperK, hyperkalemia; hypoK, hypokalemia; IHD, ischemic heart disease; K+, potassium; MRA, mineralocorticoid receptor antagonist; N, 
number.
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all-cause mortality in observational studies and meta- 
analyses, emphasizing the value of maintaining 
normokalemia.10,11 In our environment, Nuñez et al 
observed that abnormal kalemia was independently asso-
ciated with higher risk of death in a large clinical cohort of 
patients with CHF.23 Consequently, clinical practice guide-
lines already recommend close monitoring of K+ levels in 
patients with any of these conditions, particularly among 
those using RAASI medications.6–8,21,22 In this context, 
our findings provide further evidence on the actual, real- 
world epidemiological importance of this phenomenon, 
and suggest that actions and therapies aimed at 
maintaining normal K+ levels may be relevant to a very 
large number of patients. Our work gives an extensive 
view of the magnitude of chronic cardiovascular, meta-
bolic and renal conditions, how we treat them and their 
interrelation with K+ derangements.
Study Strengths
The present analysis has important strengths. The popula-
tion-based nature of the study allowed a real-world analy-
sis to be conducted on the epidemiological importance of 
K+ derangements, and minimized selection bias. Also, we 
were able to obtain exhaustive information on serum K+ 
Table 5 Multivariate Log-Binomial Regression Analysis. Risk Factors for the Prevalence of Hyperkalemia Among Adults ≥55 Years of 
Age with at Least One Relevant Condition (CHF, CKD, DM, IHD, HTN) or Taking at Least One Relevant Drug (ACEIs, ARBs, MRAs), 
MetroSud Area, Catalonia, January 1st 2015 to January 1st 2017
2015 RR 95% CI RR 95% CI
Age [55–60] 1.214 0.134 0.253 CHF 1.092 0.035 0.142
Age (60–65] 1.511 0.356, 0.469 CKD 1.804 0.558 0.622
Age (65–70] 1.74 0.498 0.61 DM 1.891 0.612, 0.662
Age (70–75] 1.887 0.578, 0.692 IHD 1.196 0.126, 0.232
Age (75–80] 2.027 0.649, 0.764 HTN 1.146 0.106, 0.167
Age (80–85] 2.019 0.642, 0.763 ACEIs 1.496 0.374, 0.431
Age (85–90] 2.004 0.624, 0.766 ARBs 1.134 0.093, 0.158
Age (90–95] 1.811 0.488, 0.699 MRAs 1.37 0.252, 0.378
Gender (male) 1.172 0.136, 0.182
2016 RR 95% CI RR 95% CI
Age 55–60 1.219 0.141, 0.254 CHF 0.974 −0.075, 0.022
Age 60–65 1.559 0.39, 0.499 CKD 1.909 0.618, 0.675
Age 65–70 1.725 0.491, 0.599 DM 1.859 0.596, 0.644
Age 70–75 1.853 0.562, 0.672 IHD 1.167 0.111, 0.197
Age 75–80 1.939 0.607, 0.718 HTN 1.124 0.087, 0.147
Age 80–85 1.867 0.566, 0.683 ACEIs 1.433 0.332, 0.388
Age 85–90 1.833 0.538, 0.675 ARBs 1.107 0.07, 0.134
Age 90–95 1.744 0.458, 0.654 MRAs 1.379 0.261, 0.381
Gender (male) 1.209 0.168, 0.212
2017 RR 95% CI RR 95% CI
Age 55–60 1.167 0.1, 0.209 CHF 1.023 −0.021, 0.067
Age 60–65 1.41 0.295, 0.401 CKD 1.839 0.582, 0.637
Age 65–70 1.678 0.466, 0.569 DM 1.845 0.589, 0.636
Age 70–75 1.765 0.516, 0.62 IHD 1.146 0.097, 0.176
Age 75–80 1.853 0.563, 0.671 HTN 1.126 0.088, 0.148
Age 80–85 1.746 0.501, 0.614 ACEIs 1.386 0.299, 0.354
Age 85–90 1.683 0.454, 0.587 ARBs 1.075 0.041, 0.104
Age 90–95 1.585 0.366, 0.555 MRAs 1.342 0.236, 0.353
Gender (male) 1.187 0.150, 0.193
Notes: Data are presented as risk ratio and 95% confidence interval. For each year, the prevalence was assessed between January 1st of the preceding year and January 1st 
of the corresponding year. 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHF, chronic heart failure; CI, confidence interval; CKD, chronic kidney 
disease; DM, diabetes mellitus; HTN, hypertension; IHD, ischemic heart disease; MRA, mineralocorticoid receptor antagonist; RR, risk ratio.
Jiménez-Marrero et al                                                                                                                                              Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                                   





























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
determinations generated in both primary and hospital care 
settings – a type of information that is usually not avail-
able in large healthcare databases, making the present 
analysis unique.
Study Limitations
Some limitations must also be discussed. First, as for 
any retrospective analysis using information generated 
from routine clinical practice and recorded in large 
administrative healthcare databases, underrecording of 
health conditions is possible. This may have resulted 
in an underestimation of the actual prevalence of each 
of the relevant conditions assessed. Also, the validity of 
some of the diagnoses, particularly those generated in 
primary care settings, may be limited.24 On the other 
hand, the information related to drug dispensing and to 
laboratory test results is expected to be very exhaustive 
and highly valid.
Second, K+ derangements were identified from labora-
tory test results generated during routine clinical practice. 
Therefore, underdetection of mild, asymptomatic derange-
ments is a possibility. Consequently, a conservative bias is 
possible, i.e., the frequency of K+ derangements, although 
already high, may be even higher in real life.
Third, information on serum K+ levels was available 
only since 2015; therefore, the study period could not be 
extended before January 1st 2015. Nevertheless, given the 
very large sample size of the study as well as its popula-
tion-based nature, we believe that the present set of ana-
lyses is sufficiently informative about the population-level 
prevalence of K+ abnormalities among RAASI users.
Finally, our choice of age threshold for study entry (55 
years of age or older) was arbitrary, and other age criteria 
could have been used. It is important to note that lower age 
thresholds would have resulted in a lower prevalence of 
chronic conditions, as younger individuals would be 
included in the denominator. On the other hand, older 
thresholds would have resulted in a higher prevalence 
not only of the conditions of interest but also of K+ 
derangements, as a consequence of selecting an older, 
typically frail population. For these reasons, we believe 
that the age threshold used was reasonable.
Conclusions
In this very large, population-based analysis including the 
whole population from the MetroSud Area in Catalonia, 55 
years of age or older, the frequency of K+ derangements and 
particularly of hyperkalemia was high among patients with 
chronic cardiovascular, metabolic and renal conditions such 
as CHF, CKD, DM, IHD or HTN, and even higher among 
those using at least one RAASI medication. CKD, DM and 
the use of ACEIs or MRAs were factors related to the pre-
valence of hyperkalemia in the multivariable analysis. The 
present findings highlight the epidemiological importance of 
K+ derangements among individuals treated with RAASI 
therapies, and point to the potential importance of interven-
tions aimed at stabilizing serum K+ levels in these patients, 
which are likely to benefit large numbers of patients.
Abbreviations
ACEI, angiotensin-converting enzyme inhibitor; ARB, angio-
tensin II receptor blocker; ARNI, angiotensin II receptor 
blocker neprilysin inhibitor; ATC, Anatomical Therapeutic 
Chemical (coding system); CCS, Clinical Classifications 
Software; CHF, chronic heart failure; CKD, chronic kidney 
disease; DM, diabetes mellitus; HTN, hypertension; ICD- 
9-CM, International Classification of Diseases, 9th Revision, 
Clinical Modification; ICD-10, International Classification of 
Diseases, 10th Revision; ICS, Catalan Institute of Health 
(Institut Catala de Salut); IHD, ischemic heart disease; K+, 
potassium; MetroSud, Metropolitana Sud healthcare area; 
MRA, mineralocorticoid receptor antagonist; RAAS, renin– 
angiotensin–aldosterone system; RAASI, RAAS inhibitor; RI, 
renin inhibitor.
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